Toxicology, Pathology and Biodistribution Core (TPB Core)
Toxicology, Pathology and Biodistribution Core (TPB Core)
批准号:
7982610
负责人:
LIONEL David LEWIS
金额:
$9.59万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-01 至 2015-08-31
关键词:
AbdomenAlgorithmsAnatomyAnimalsBiodistributionBiostatistics CoreCCNE1 geneCancer ModelCellsData AnalysesDendritic CellsDepositionDevelopmentDrug KineticsFeedbackFluorescent ProbesFunctional disorderFutureGoalsGoldHumanImaging TechniquesIn VitroIndividualInjuryIronLocationMagnetic Resonance ImagingMalignant neoplasm of ovaryMammary NeoplasmsMethodsModelingMovementMusNormal tissue morphologyOpticsOrganOvarianParticipantPathologicPathologyPeptidesPlasmaPlayProductionPrussian blueRelative (related person)Research PersonnelResearch Project GrantsRiskRoleSafetySpectrum AnalysisTechniquesTimeTissuesToxic effectToxicologyTreatment EfficacyValidationWorkcancer cellcytotoxiccytotoxicitydesignin vivoiron oxidemagnetic fieldnanoparticlepre-clinicaltumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The Toxicology, Pathology, and Biodistribution Core will provide qualitative and quanfitative assessment of the movement and deposition of mNPs in ail major organ tissues as well as individual cells in specific settings. The TPB core will also provide dedicated and comprehensive pharmacokinetic (Lewis), human and animal pathology/pathophysiology (Memoli and Hoopes) and TEM/SEM (Daghlian) expertise for potential cellular and/or tissue change resulfing from the mNPs (iron, coafings, targefing peptides, fluorescent probes etc and/or the alternafing magnetic field (AMF) exposure. Since it is the primary goal of the entire DCCNE application to opfimize methods for the observation and selectively delivery of mNP/lron to cancer cells for subsequent cytotoxic excitation, the assessment and quantification of iron levels in cells and fissues (Prussian Blue histomorphometry and ICP-MS) and the resultant pathologic effects in the tumor and normal fissues, is of paramount importance.
The TPB Core will be a central partcipant in the determination ofthe relafive ability ofthe various NP
physical parameters, coatings, internalizing vs noninternalizing ScFv peptides to selectively target mNP /iron to cancer cells in vitro and in vivo (Project 1). In addition, TEM will allow an accurate assessment of the volume and anatomic location of the various NPs with respect to effective excitation and cytotoxicity.
TPB assessments will determine which peptides have the most targeting promise for future use in preclinical in vivo ovarian and breast tumor models (Projects 2 and 3). In Project 2, the TPB will play an essential role determining the accuracy and sensitivity ofthe mNP in vivo imaging techniques. Pathologic co-registration and validation of changes observed by noninvasive imaging techniques such as optical spectroscopy and MRI remains the gold standard for determining the sensitivity and reliability of new imaging techniques. In Project 3, the use of ICP-MS and Prussian Blue histomorphometry mNP /iron quantificafion techniques will allow investigators to determine the absolute role of mNP/lron content in tumor treatment efficacy studies. In Project 4, the TPB Core will be important in determining the level of iron that is taken up by the ovarian cancer dendritic cells, cancer cells and other abdominal tissues that are exposed to the ip delivered mNPs. Since the targeted NP exposure field, in this cancer model, is large, there Is a risk of normal tissue injury. Pathologic assessment of these mice will be extremely important for safety and the understanding of toxicity/efficacy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
7HP349, an Integrin Activator to Treat Patients With anti-PD-1 Resistant Solid Tumors
-
批准号:10761171
-
项目类别:
-
资助金额:$99.92万
-
财政年份:2023
-
负责人:LIONEL David LEWIS
-
依托单位:
Development of 7HP349, an oral integrin activator to enhance therapeutic responses to immune checkpoint inhibitors
-
批准号:10261525
-
项目类别:
-
资助金额:$101.56万
-
财政年份:2020
-
负责人:LIONEL David LEWIS
-
依托单位:
CLINICAL PHARMACOLOGY SHARED RESOURCE
-
批准号:7944619
-
项目类别:
-
资助金额:$15.14万
-
财政年份:2009
-
负责人:LIONEL David LEWIS
-
依托单位:
PROTOCOL REVIEW AND MONITORING SYSTEM
-
批准号:7944683
-
项目类别:
-
资助金额:$4.64万
-
财政年份:2009
-
负责人:LIONEL David LEWIS
-
依托单位:
Clinical Molecular
-
批准号:6989452
-
项目类别:
-
资助金额:$10.23万
-
财政年份:2004
-
负责人:LIONEL David LEWIS
-
依托单位:
Clinical Pharmacology (CP)
-
批准号:10554245
-
项目类别:
-
资助金额:$10.99万
-
财政年份:1997
-
负责人:LIONEL David LEWIS
-
依托单位:
Clinical Pharmacology (CP)
-
批准号:8804008
-
项目类别:
-
资助金额:$11.82万
-
财政年份:1997
-
负责人:LIONEL David LEWIS
-
依托单位:
Clinical Pharmacology (CP)
-
批准号:10311226
-
项目类别:
-
资助金额:$10.99万
-
财政年份:1997
-
负责人:LIONEL David LEWIS
-
依托单位:
Protocol Review and Monitoring System (PRMS)
-
批准号:10554303
-
项目类别:
-
资助金额:$7.1万
-
财政年份:1997
-
负责人:LIONEL David LEWIS
-
依托单位:
Protocol Review and Monitoring System (PRMS)
-
批准号:10311241
-
项目类别:
-
资助金额:$7.1万
-
财政年份:1997
-
负责人:LIONEL David LEWIS
-
依托单位:
Clinical Molecular
-
批准号:7332202
-
项目类别:
-
资助金额:$23.96万
-
财政年份:--
-
负责人:LIONEL David LEWIS
-
依托单位:
Clinical Pharmacology (CP)
-
批准号:9561223
-
项目类别:
-
资助金额:$0.18万
-
财政年份:--
-
负责人:LIONEL David LEWIS
-
依托单位:
PROTOCOL REVIEW AND MONITORING SYSTEM
-
批准号:8255530
-
项目类别:
-
资助金额:$4.33万
-
财政年份:--
-
负责人:LIONEL David LEWIS
-
依托单位:
CLINICAL PHARMACOLOGY SHARED RESOURCE
-
批准号:8015000
-
项目类别:
-
资助金额:$16.12万
-
财政年份:--
-
负责人:LIONEL David LEWIS
-
依托单位:
Toxicology, Pathology and Biodistribution Core (TPB Core)
-
批准号:8710053
-
项目类别:
-
资助金额:$15.85万
-
财政年份:--
-
负责人:LIONEL David LEWIS
-
依托单位:
CLINICAL PHARMACOLOGY SHARED RESOURCE
-
批准号:8787215
-
项目类别:
-
资助金额:$12.44万
-
财政年份:--
-
负责人:LIONEL David LEWIS
-
依托单位:
Protocol Review and Monitoring (PRMS)
-
批准号:9204745
-
项目类别:
-
资助金额:$6.39万
-
财政年份:--
-
负责人:LIONEL David LEWIS
-
依托单位:
Protocol Review and Monitoring (PRMS)
-
批准号:9758112
-
项目类别:
-
资助金额:$0.17万
-
财政年份:--
-
负责人:LIONEL David LEWIS
-
依托单位:
CLINICAL PHARMACOLOGY SHARED RESOURCE
-
批准号:8376245
-
项目类别:
-
资助金额:$14.23万
-
财政年份:--
-
负责人:LIONEL David LEWIS
-
依托单位:
CLINICAL PHARMACOLOGY SHARED RESOURCE
-
批准号:8255518
-
项目类别:
-
资助金额:$14.16万
-
财政年份:--
-
负责人:LIONEL David LEWIS
-
依托单位:
海外基金